

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

409 AUG 06 2002

1614 #3
8/26/02
82

CERTIFICATE OF MAILING

TECH CENTER 1600/2900

I hereby certify that this paper is being deposited with the U.S. Postal Service as first class mail on the date indicated below in an envelope addressed to: Assistant Commissioner for Patents, Washington D.C. 20231.

Name of Person Mailing: Iris Weise

Signature:

Iris Weise

Date:

7-22-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Supplemental Information Disclosure Statement Address to: Assistant Commissioner of Patents Washington, D.C. 20231	First Named Inventor	Becker, Cyrus Kephra et al.
	Application Number	10/040,319 ✓
	Filing Date	January 2, 2002 ✓
	Group Art Unit	1614
	Examiner	
	Attorney Docket No.	R0079C-REG
	Title	Quinazalone Derivatives as Alpha 1A/B Adrenergic Receptor Antagonists ✓

Sir:

Supplemental Information Disclosure Statement

Applicants wish to bring to the attention of the Examiner an International Search Report, dated May 31, 2002, for the PCT patent application that is a counterpart of the subject application. The attached Information Disclosure Statement is filed in compliance with 37 CFR §1.56, and the documents cited therein may be material to the patentability of the subject patent application. References listed on the International Search Report that have previously been cited in the U.S. application are not again listed on the enclosed Form 1449.

[X] Attached are:


- A copy of the PCT Search Report (list report),
- Form 1449, "List of References Cited," with copy of each reference cited
- Return postcard

[X] The Information Disclosure Statement is being submitted (a) within three months of the filing date, or (b) before the mailing date of the first Office Action. **Therefore, no fee is due under 37 CFR 1.97(b).**

[X] Applicants believe that no fees are due. However, should this not be the case, the Commissioner is hereby authorized to charge any additional fees that may be required to Deposit Account No. 18-1700.

The Examiner is respectfully requested to consider these documents and to make them of record in the subject application.

Respectfully submitted,



Rohan Peries
Reg. No. 35,752
Attorney for Applicant(s)

Roche Bioscience
Patent Law Dept.
3401 Hillview Avenue - M/S A2-250
Palo Alto, CA 94304
Direct Phone (650) 855-5311

Date: 7/22/02